Nature Search

Navigating the path forward for evidence-based management of long COVID

The US National Institute of Allergy and Infectious Diseases (NIAID) and the Foundation for the National Institutes of Health (FNIH) held a three-day workshop to assess the landscape of long COVID clinical studies and develop plans for the RECOVER-TLC clinical trials program.

Joseph J. Breen
Robert W. Eisinger
Jeanne M. Marrazzo
News & Views19 Mar 2025
Nature Immunology

Volume: 26, P: 536-539
Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial

Analysis of antibody responses to COVID-19 vaccines encoding variant-specific spike, with or without ancestral spike, suggests no loss of neutralization of the ancestral virus with variant-only vaccines, which may simplify future vaccine updates.

Angela R. Branche
Nadine G. Rouphael
Elizabeth Brown
ResearchOpen Access28 Aug 2023
Nature Medicine

Volume: 29, P: 2334-2346
Correction: Corrigendum: Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies

Surender Khurana
Sandra Fuentes
John H Beigel
Amendments and Corrections07 Feb 2017
Nature Medicine

Volume: 23, P: 264
Differential human antibody repertoires following Zika infection and the implications for serodiagnostics and disease outcome

In the current study, the authors profile the IgG and IgM antibody repertoires that develop over 7 days following acute Zika virus infection. Using urine and serum samples from infected human patients the authors identify new biomarkers for serodiagnosis of Zika virus.

Supriya Ravichandran
Megan Hahn
Surender Khurana
ResearchOpen Access26 Apr 2019
Nature Communications

Volume: 10, P: 1-14
Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus

Avian influenza vaccines in the US strategic stockpile elicit immune responses that recognize the clade of avian influenza circulating in cows and could be a resource before newer vaccines are approved and deployed.

Surender Khurana
Lisa R. King
Hana Golding
Research16 Jul 2024
Nature Medicine

Volume: 30, P: 2771-2776
Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies

Surender Khurana and colleagues analyzed the antibody repertoire in healthy individuals after vaccination against Ebola virus using a VSV-Ebola vaccine and identify a strong contribution of IgM antibodies to the virus-neutralizing response.

Surender Khurana
Sandra Fuentes
John H Beigel
Research31 Oct 2016
Nature Medicine

Volume: 22, P: 1439-1447
A network analysis of carbapenem-resistant Klebsiella pneumoniae among healthcare facilities

Courtney L. Luterbach
Dana K. Pasquale
David Roach
ResearchOpen Access29 Jul 2025
Scientific Reports

Volume: 15, P: 1-11
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants

Kirsten E. Lyke
Robert L. Atmar
Jennifer A. Whitaker
ResearchOpen Access11 Jul 2023
npj Vaccines

Volume: 8, P: 1-10
Erratum: IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, correlates with IGHV utilization shifts and varies by ethnicity

Yuval Avnir
Corey T. Watson
Wayne A. Marasco
Amendments and CorrectionsOpen Access29 Apr 2016
Scientific Reports

Volume: 6, P: 1-2
IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, correlates with IGHV utilization shifts and varies by ethnicity

Yuval Avnir
Corey T. Watson
Wayne A. Marasco
ResearchOpen Access16 Feb 2016
Scientific Reports

Volume: 6, P: 1-13

Search

Navigating the path forward for evidence-based management of long COVID

Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial

Correction: Corrigendum: Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies

Differential human antibody repertoires following Zika infection and the implications for serodiagnostics and disease outcome

Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus

Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies

A network analysis of carbapenem-resistant Klebsiella pneumoniae among healthcare facilities

Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants

Erratum: IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, correlates with IGHV utilization shifts and varies by ethnicity

IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, correlates with IGHV utilization shifts and varies by ethnicity

Search

Quick links

Search

Filter By:

Search

Quick links